Amgen’s newly created subsidiary, Pillartree Limited, will acquire Horizon Therapeutics for $116.50 per share in cash. That’s a premium of 19.7% above the closing price of $97.29 on Dec. 9, 2022.

New research published in Annals of Rheumatic Diseases and Hypertension examined the impact medications for different non-cardiovascular conditions can have on a patient's heart health.

Diagnostic catheters, ablation catheters and stents are just some of the solutions cardiologists are now struggling to obtain.

A new scientific statement from the American Heart Association examined the potential impact of many therapies, including fish oil supplements, lily of the valley and yoga.

Researchers have completed a new analysis of the Evolut Pro and Pro+ devices from Medtronic and the Sapien 3 Ultra devices from Edwards Lifesciences, sharing the results in JACC: Cardiovascular Interventions.

Oversized devices are becoming more common as time goes on, which suggests operators are growing increasingly comfortable with this treatment choice.

“There is a crucial need to develop synthetic vascular graft materials that will increase the rate of long-term functions,” one researcher said. Could materials derived from seaweed help fill that need?

Getinge has provided a detailed breakdown of the shortage, stating that it is not yet clear when it may be over. The FDA said it will keep a close eye on the situation and provide updates when possible.